Drugs in Dev. Musculoskeletal
Phase IV
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Allergan Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks (and at least 16 weeks for pediatric upper limb spasticity).
Product Name : Dysport
Product Type : Protein
Upfront Cash : Inapplicable
January 15, 2021
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Allergan Aesthetics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.
Product Name : Dysport
Product Type : Protein
Upfront Cash : Inapplicable
May 23, 2020
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
